Somewhat Positive Media Coverage Somewhat Unlikely to Impact Spark Therapeutics (ONCE) Stock Price
News articles about Spark Therapeutics (NASDAQ:ONCE) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Spark Therapeutics earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.461836843669 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights (finance.yahoo.com)
- Mizuho Securities Initiates a Buy Rating on Spark Therapeutics – Analyst Ratings (analystratings.com)
- Spark Therapeutics (ONCE) Earns Buy Rating from Analysts at Mizuho (americanbankingnews.com)
- Spark Therapeutics (ONCE) Stock Rating Reaffirmed by Royal Bank of Canada (americanbankingnews.com)
- Trending Hot Stock’s Analysis – Spark Therapeutics Inc (NASDAQ: ONCE) – Stocks Pen (stockspen.com)
Spark Therapeutics (NASDAQ:ONCE) opened at $54.80 on Wednesday. The firm has a market capitalization of $2,030.00, a PE ratio of -7.61 and a beta of 3.02. Spark Therapeutics has a 12-month low of $41.06 and a 12-month high of $91.75.
In other news, insider Katherine A. High sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total transaction of $356,600.00. Following the completion of the transaction, the insider now owns 215,000 shares in the company, valued at $15,333,800. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Stephen W. Webster sold 10,000 shares of Spark Therapeutics stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $70.14, for a total value of $701,400.00. Following the completion of the transaction, the chief financial officer now owns 12,500 shares of the company’s stock, valued at approximately $876,750. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,018 shares of company stock valued at $1,058,834. Company insiders own 7.30% of the company’s stock.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.